Despite these limitations, this study provides new molecular biomarkers for early AKI diagnosis in gastrointestinal cancer patients, particularly CDK1 and STAT1, whose combined detection shows potential for early kidney injury assessment and offers a solid foundation for clinical application. Here, CDK1 is linked to injury.